Carvedilol attenuates carbon tetrachloride-induced liver fibrosis and hepatic sinusoidal capillarization in mice

References

• Schuppan D, Ashfaq-Khan M, Yang AT, Kim YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol. 2018;68–69:435–51.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Li Y, Jain A, et al. Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells. Nanomedicine. 2018;14(1):51–61. doi:10.1016/j.nano.2017.08.01728890106
   PubMed Web of Science ®Google Scholar
• Jain A, Barve A, Zhao Z, Jin W, Cheng K. Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery. Mol Pharm. 2017;14(5):1517–1527. doi:10.1021/acs.molpharmaceut.6b0093328026957
   PubMed Web of Science ®Google Scholar
• Ueha S, Shand FH, Matsushima K. Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis. Front Immunol. 2012;3:71. doi:10.3389/fimmu.2012.0019822566952
   PubMed Web of Science ®Google Scholar
• Munoz-Ortega MH, Llamas-Ramirez RW, Romero-Delgadillo NI, et al. Doxazosin treatment attenuates carbon tetrachloride-induced liver fibrosis in hamsters through a decrease in transforming growth factor beta secretion. Gut Liver. 2016;10(1):101–108. doi:10.5009/gnl1445926573293
   PubMed Web of Science ®Google Scholar
• Kisseleva T. The origin of fibrogenic myofibroblasts in fibrotic liver. Hepatology. 2017;65(3):1039–1043. doi:10.1002/hep.v65.327859502
   PubMed Web of Science ®Google Scholar
• Mimche PN, Lee CM, Mimche SM, et al. EphB2 receptor tyrosine kinase promotes hepatic fibrogenesis in mice via activation of hepatic stellate cells. Sci Rep. 2018;8(1):2532. doi:10.1038/s41598-018-20926-929416088
   PubMed Web of Science ®Google Scholar
• Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol. 2010;53(5):976–980. doi:10.1016/j.jhep.2010.01.03220800926
   PubMed Web of Science ®Google Scholar
• Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–1669. doi:10.1053/j.gastro.2008.01.07418471545
   PubMed Web of Science ®Google Scholar
• Cogger VC, McNerney GP, Nyunt T, et al. Three-dimensional structured illumination microscopy of liver sinusoidal endothelial cell fenestrations. J Struct Biol. 2010;171(3):382–388. doi:10.1016/j.jsb.2010.06.00120570732
   PubMed Web of Science ®Google Scholar
• Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002;1(1):1. doi:10.1186/1476-5926-1-112437787
   PubMedGoogle Scholar
• Yao Q, Lin Y, Li X, Shen X, Wang J, Tu C. Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis. Toxicol Lett. 2013;222(1):72–82. doi:10.1016/j.toxlet.2013.06.24023845850
   PubMed Web of Science ®Google Scholar
• Decaris ML, Li KW, Emson CL, et al. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood. Hepatology. 2017;65(1):78–88. doi:10.1002/hep.2886027706836
   PubMed Web of Science ®Google Scholar
• Kantari-Mimoun C, Castells M, Klose R, et al. Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis. Hepatology. 2015;61(6):2042–2055. doi:10.1002/hep.2763525475053
   PubMed Web of Science ®Google Scholar
• Li Z, Ding Q, Ling LP, et al. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells in vivo and in vitro by activating AMP-activated protein kinase. World J Gastroenterol. 2018;24(7):819–832. doi:10.3748/wjg.v24.i7.81929467552
   PubMed Web of Science ®Google Scholar
• Kong LJ, Li H, Du YJ, et al. Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl4-induced fibrotic mice. Mol Med Rep. 2017;15(5):2604–2610. doi:10.3892/mmr.2017.632528447731
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Kedarisetty CK, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut. 2017;66(10):1838–1843. doi:10.1136/gutjnl-2016-31173527298379
   PubMed Web of Science ®Google Scholar
• de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53(4):762–768. doi:10.1016/j.jhep.2010.01.03220638742
   PubMed Web of Science ®Google Scholar
• Araujo Junior RF, Garcia VB, Leitao RF, et al. Carvedilol improves inflammatory response, oxidative stress and fibrosis in the alcohol-induced liver injury in rats by regulating kuppfer cells and hepatic stellate cells. PLoS One. 2016;11(2):e0148868. doi:10.1371/journal.pone.014886826891124
   PubMed Web of Science ®Google Scholar
• Hakucho A, Liu J, Liu X, Fujimiya T. Carvedilol improves ethanol-induced liver injury via modifying the interaction between oxidative stress and sympathetic hyperactivity in rats. Hepatol Res. 2014;44(5):560–570. doi:10.1111/hepr.2014.44.issue-523607506
   PubMed Web of Science ®Google Scholar
• Liu J, Takase I, Hakucho A, Okamura N, Fujimiya T. Carvedilol attenuates the progression of alcohol fatty liver disease in rats. Alcohol Clin Exp Res. 2012;36(9):1587–1599. doi:10.1111/j.1530-0277.2012.01773.x22413959
   PubMed Web of Science ®Google Scholar
• Ding Q, Tian XG, Li Y, Wang QZ, Zhang CQ. Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. World J Gastroenterol. 2015;21(32):9566–9576. doi:10.3748/wjg.v21.i10.293726327764
   PubMed Web of Science ®Google Scholar
• Baig MS, Yaqoob U, Cao S, Saqib U, Shah VH. Non-canonical role of matrix metalloprotease (MMP) in activation and migration of hepatic stellate cells (HSCs). Life Sci. 2016;155:155–160. doi:10.1016/j.lfs.2016.04.03127140333
   PubMed Web of Science ®Google Scholar
• Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009;50(3):604–620. doi:10.1016/j.jhep.2008.12.01119157625
   PubMed Web of Science ®Google Scholar
• An YA, Sun K, Joffin N, et al. Angiopoietin-2 in white adipose tissue improves metabolic homeostasis through enhanced angiogenesis. eLife. 2017;6. doi:10.7554/eLife.24071
   Web of Science ®Google Scholar
• Jiang H, Qin XJ, Li WP, Ma R, Wang T, Li ZQ. Effects of Shu Gan Jian Pi formula on rats with carbon tetrachlorideinduced liver fibrosis using serum metabonomics based on gas chromatographytime of flight mass spectrometry. Mol Med Rep. 2017;16(4):3901–3909. doi:10.3892/mmr.2017.707829067456
   PubMed Web of Science ®Google Scholar
• Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology. 2009;50(4):1294–1306. doi:10.1002/hep.2312319711424
   PubMed Web of Science ®Google Scholar
• Nakano Y, Nakao S, Sumiyoshi H, et al. Identification of a novel alpha-fetoprotein-expressing cell population induced by the Jagged1/Notch2 signal in murine fibrotic liver. Hepatol Commun. 2017;1(3):215–229. doi:10.1002/hep4.110329404455
   PubMed Web of Science ®Google Scholar
• Tripathi D, Hayes PC. Beta-blockers in portal hypertension: new developments and controversies. Liver Int. 2014;34(5):655–667. doi:10.1111/liv.2014.34.issue-524134058
   PubMed Web of Science ®Google Scholar
• Li T, Ke W, Sun P, et al. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 2016;6(5):e010902. doi:10.1136/bmjopen-2015-010902
   PubMed Web of Science ®Google Scholar
• Ding Q, Li Z, Liu B, Ling L, Tian X, Zhang C. Propranolol prevents liver cirrhosis by inhibiting hepatic stellate cell activation mediated by the PDGFR/Akt pathway. Hum Pathol. 2018;76:37–46. doi:10.1016/j.humpath.2018.02.01829514109
   PubMed Web of Science ®Google Scholar
• Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology. 2008;48(3):920–930. doi:10.1002/hep.v48:318613151
   PubMed Web of Science ®Google Scholar
• Gracia-Sancho J, Maeso-Diaz R, Fernandez-Iglesias A, Navarro-Zornoza M, Bosch J. New cellular and molecular targets for the treatment of portal hypertension. Hepatol Int. 2015;9(2):183–191. doi:10.1007/s12072-015-9613-525788198
   PubMed Web of Science ®Google Scholar
• Lee TF, Mak KM, Rackovsky O, et al. Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP). J Cell Physiol. 2010;223(3):648–657.20143336
   PubMed Web of Science ®Google Scholar
• Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125–172.18195085
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang F, Kong D, et al. Tetramethylpyrazine inhibits angiotensin II-induced activation of hepatic stellate cells associated with interference of platelet-derived growth factor beta receptor pathways. Febs J. 2014;281(12):2754–2768. doi:10.1111/febs.1275824725506
   PubMed Web of Science ®Google Scholar
• DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol. 2004;287(4):G757–763. doi:10.1152/ajpgi.00017.200415191879
   PubMed Web of Science ®Google Scholar
• Elvevold K, Smedsrod B, Martinez I. The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity. Am J Physiol Gastrointest Liver Physiol. 2008;294(2):G391–400. doi:10.1152/ajpgi.00167.200718063708
   PubMed Web of Science ®Google Scholar
• Xie G, Choi SS, Syn WK, et al. Hedgehog signalling regulates liver sinusoidal endothelial cell capillarisation. Gut. 2013;62(2):299–309. doi:10.1136/gutjnl-2011-30149422362915
   PubMed Web of Science ®Google Scholar
• DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology. 2015;61(5):1740–1746. doi:10.1002/hep.2737625131509
   PubMed Web of Science ®Google Scholar
• Huebert RC, Jagavelu K, Liebl AF, et al. Immortalized liver endothelial cells: a cell culture model for studies of motility and angiogenesis. Lab Invest. 2010;90(12):1770–1781. doi:10.1038/labinvest.2010.13220644520
   PubMed Web of Science ®Google Scholar
• Prystupa A, Boguszewska-Czubara A, Bojarska-Junak A, Torun-Jurkowska A, Rolinski J, Zaluska W. Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. Ann Agric Environ Med. 2015;22(2):325–328. doi:10.5604/12321966.115208826094532
   PubMed Web of Science ®Google Scholar
• Lin HC, Huang YT, Yang YY, et al. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. J Gastroenterol Hepatol. 2014;29(5):1073–1082. doi:10.1111/jgh.1248024325631
   PubMed Web of Science ®Google Scholar
• Bona S, Rodrigues G, Moreira AJ, et al. Antifibrogenic effect of melatonin in rats with experimental liver cirrhosis induced by carbon tetrachloride. JGH Open. 2018;2(4):117–123. doi:10.1002/jgh3.1205530483575
   PubMed Web of Science ®Google Scholar
• Novo E, Cannito S, Zamara E, et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol. 2007;170(6):1942–1953. doi:10.2353/ajpath.2007.06003117525262
   PubMed Web of Science ®Google Scholar
• Mallat A, Lotersztajn S. Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis. Am J Physiol Cell Physiol. 2013;305(8):C789–799. doi:10.1152/ajpcell.00026.201323903700
   PubMed Web of Science ®Google Scholar